Press release
Idiopathic Pulmonary Fibrosis Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts
Idiopathic Pulmonary Fibrosis
What Is the Expected Idiopathic Pulmonary Fibrosis Market Size During the Forecast Period?
The market size for idiopathic pulmonary fibrosis has consistently expanded in the past few years. A growth from $4.15 billion in 2024 to $4.39 billion in 2025, representing a compound annual growth rate (CAGR) of 5.6%, is predicted. Factors such as an increasing elderly population, lack of therapeutic options, growing knowledge of the disease, and advancement in healthcare infrastructure have contributed to the growth previously observed.
The market size of idiopathic pulmonary fibrosis is anticipated to experience robust growth in the forthcoming years. It is forecasted to reach $5.74 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%. The forecasted period's growth can be credited to factors such as enhanced research and development, precision medicine methods, a rise in disease prevalence, progress in biomarker development, and government initiatives and funding. The significant trends of this projected period encompass advancements in diagnostic techniques, the emergence of targeted therapies, the rise of telemedicine and remote monitoring, combination therapies, and improvements in lung transplants.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12579
What Are the High-Growth Segments in the Idiopathic Pulmonary Fibrosis Market?
The idiopathic pulmonary fibrosis market covered in this report is segmented -
1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals And Clinics, Other End Users
Subsegments:
1) By Nintedanib: Indications, Dosage Forms, Administration Routes
2) By Pirfenidone: Indications, Dosage Forms, Administration Routes
3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp
What Key Drivers Are Expected to Influence Future Idiopathic Pulmonary Fibrosis Market Growth?
The idiopathic pulmonary fibrosis market is anticipated to grow due to the increasing occurrence of fibrotic diseases. Fibrotic diseases, otherwise known as fibrosis, are medical conditions characterized by the overproduction and buildup of fibrous connective tissue in various organs or tissues. Drugs for idiopathic pulmonary fibrosis can alleviate lung fibrosis and inflammation by targeting multiple signal pathways involved in fibrosis. For example, the American Lung Association stated in December 2022 that roughly 207,000 people in the United States were affected, and there were approximately 58,000 new cases of idiopathic pulmonary fibrosis diagnosed each year, predominantly in men over 50 years old. Consequently, an increase in fibrotic disease prevalence propels the growth of the idiopathic pulmonary fibrosis market.
Which Companies Hold the Largest Share Across Different Idiopathic Pulmonary Fibrosis Market Segments?
Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
What Trends Are Driving Growth in The Idiopathic Pulmonary Fibrosis Market?
Product innovation has emerged as an important trend in the idiopathic pulmonary fibrosis market. Companies in the sector concentrate on the creation of innovative goods, strengthening their standing and achieving a competitive edge. For example, in May 2022, Sandoz, a manufacturer of generic and biosimilar medicines based in Switzerland, initiated a generic pirfenidone, marking it as the first AB-rated substitute to Genentech's Esbriet, used for idiopathic pulmonary fibrosis (IPF) treatment. This prescription medication, which can be taken orally, is now available to patients through specialty pharmacies. Moreover, eligible patients can avail of a benefit from a USD 0 co-pay scheme.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
What Are the Emerging Geographies for The Idiopathic Pulmonary Fibrosis Market Growth?
North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Idiopathic Pulmonary Fibrosis Market?
2. What is the CAGR expected in the Idiopathic Pulmonary Fibrosis Market?
3. What Are the Key Innovations Transforming the Idiopathic Pulmonary Fibrosis Industry?
4. Which Region Is Leading the Idiopathic Pulmonary Fibrosis Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts here
News-ID: 3998343 • Views: …
More Releases from The Business Research Company
Kidney Cancer Diagnostics And Therapeutics Industry Report 2025-2034: Market Dyn …
The Kidney Cancer Diagnostics And Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Kidney Cancer Diagnostics And Therapeutics Market Size During the Forecast Period?
The market for kidney cancer diagnostics and therapeutic treatments has experienced a significant expansion in the recent…
Evolving Market Trends In The Irritable Bowel Syndrome (IBS) Treatment Industry: …
The Irritable Bowel Syndrome (IBS) Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Irritable Bowel Syndrome (IBS) Treatment Market Size During the Forecast Period?
The market size for the treatment of irritable bowel syndrome (IBS) has seen rapid expansion in recent…
Rising Expansion Of Chemical Industry To Drive Market Growth: Key Factor Driving …
The Internet of Things (IoT) in the chemical Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Internet of Things (IoT) in the chemical Market Size During the Forecast Period?
In recent times, the size of the chemical market that incorporates internet of…
Inhalable Drugs Industry Report 2025-2034: Market Dynamics, Trends, And Forecast …
The Inhalable Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Inhalable Drugs Market Size During the Forecast Period?
In recent times, there has been a robust enlargement of the inhalable drugs market. Projected expansion from $35.06 billion in 2024 to $37.27…
More Releases for Idiopathic
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In…
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments.
Get Sample…
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
Juvenile Idiopathic Arthritis Therapeutics Market
JIA is also known as juvenile idiopathic arthritis and is the most common inflammatory arthritis of childhood, musculoskeletal pain is a common symptom in childhood and is usually benign and self-resolving. JIA is affected to children who are under age 17. Recognizing rare but treatable causes, including inflammatory, malignant and infectious etiologies, remains a constant challenge. According to the American College of Rheumatology, Juvenile idiopathic arthritis affects one in 1000…
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation…
